Article

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

2022-12-16

Abstract excerpt

<h4>ABSTRACT</h4> Synergistic drug combinations are an attractive anticancer strategy but prove challenging to identify. Here we present a stepwise approach consisting in revealing core cancer vulnerabilities and exploiting them through drug combination screen to uncover synergistic treatments for glioblastoma patients. <h4>Methods</h4> We established an innovative method, based on high-throughput screening, tar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b4919e1e-898d-5352-af1c-40cdf3780203
DOI: 10.1101/2022.12.14.520491

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergismsDOI 10.1101/2022.12.14.520491Read

Drug and disease signature integration identifies synergistic combinations in glioblastomaSemantic proximity Read

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitorsSemantic proximity Read

MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCERSemantic proximity Read

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.Semantic proximity Read

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for GlioblastomaSemantic proximity Read

High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.Semantic proximity Read

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaSemantic proximity Read

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Semantic proximity Read

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read